Literature DB >> 1376654

Immune changes in HIV-1 infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens.

H Z Bass1, P Nishanian, W D Hardy, R T Mitsuyasu, E Esmail, W Cumberland, J L Fahey.   

Abstract

Human immunodeficiency virus type 1(HIV-1) induces extensive immune cell alterations which can be detected by changes both in serum levels of soluble immune activation products and in several lymphoid phenotypic markers. The current studies were conducted in 70 HIV-1 seropositive subjects to determine whether changes among four important serum immune activation markers (neopterin, beta-2 microglobulin, soluble CD8, and soluble IL-2 receptor) and seven lymphoid phenotypic markers (CD38, HLA-DR, CD57, CD11b, CD45RA, leu8, and CD71) reflect similar or disparate aspects of immune pathology. On the basis of correlation coefficient calculation, four groups of related markers (Fig. 1) were identified: Group A, sIL-2R was related to group B where serum neopterin, beta 2M, sCD8 levels, and lymphocyte CD38 antigen expression correlated closely. Loss of CD45RA or Leu 8 antigens in group C correlated with group B and D markers increase. HLA-D in group D was a more distantly related immune activation marker. Phenotypic markers CD57, CD11b, and CD71 did not correlate with the immune activation processes reflected by the serum and phenotypic marker groups A-D. Correlations between serum and certain lymphoid phenotypic markers were generally stronger later in HIV-1 infection when CD4 levels were less than 500/mm3. This study provides information for selecting markers for investigating immune changes in HIV-1 infection and immune-related diseases. Many serum and lymphoid phenotypic markers reflect related aspects of immune dysregulation. However, some markers can indicate different aspects of disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376654     DOI: 10.1016/0090-1229(92)90060-2

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  18 in total

Review 1.  Monitoring patients with HIV disease.

Authors:  M Helbert; J Breuer
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 2.  Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection.

Authors:  J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

Review 3.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

4.  Activated peripheral CD8 lymphocytes express CD4 in vivo and are targets for infection by human immunodeficiency virus type 1.

Authors:  S Imlach; S McBreen; T Shirafuji; C Leen; J E Bell; P Simmonds
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Naive and memory T-cells in HIV-infected children.

Authors:  M Duse; P Airò; E Prati; A Soresina; L D Notarangelo; R Cattaneo; A G Ugazio
Journal:  Eur J Pediatr       Date:  1994-04       Impact factor: 3.183

6.  Relation of impaired lymphocyte proliferative function to other major human immunodeficiency virus type 1-induced immunological changes.

Authors:  H Z Bass; J L Fahey; P Nishanian; R Detels; W Cumberland; M Kemeny; S Plaeger
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

7.  Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes.

Authors:  A Kalinkovich; G Livshits; H Engelmann; N Harpaz; R Burstein; M Kaminsky; D Wallach; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

8.  Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures.

Authors:  N Aziz; P Nishanian; J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

9.  Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers.

Authors:  S Resino; M L Abad; J Navarro; J M Bellón; S Sánchez-Ramón; M Angeles Muñoz-Fernández
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

10.  Cell cycling in HIV infection: analysis of in vivo activated lymphocytes.

Authors:  M Mahalingam; A Pozniak; T J McManus; D Vergani; M Peakman
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.